Overview of the Bangladesh version of ibrutinib/ibrutinib

Ibrutinib/Ibrutinib, as a highly effective kinase inhibitor, has been widely used in the treatment of a variety of hematological malignancies, and has shown significant efficacy against chronic graft-versus-host disease (cGVHD) that occurs after allogeneic stem cell transplantation. With the expansion of its global market, not only the original drug has been launched in multiple domestic and foreign markets, but the Bangladeshi version of ibrutinib generics has also been released, providing patients with new treatment options.

These Bangladeshi generic drugs are produced by well-known manufacturers such as Yaopin International, Everest Pharmaceuticals, and Beacon Pharmaceuticals. Although there are slight differences in production specifications and prices from the original drugs, their core drug ingredients are consistent with the original drugs, ensuring the similarity in therapeutic effects.

The mechanism of action of ibrutinib is that it can accurately fight cancer B cells. By blocking the Bruton tyrosine kinase (BTK) signaling pathway, it effectively reduces the survival and reproduction capabilities of B cells. This property makes ibrutinib excellent in the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM). At the same time, ibrutinib can also inhibit the activity of interleukin-2-inducible T-cell kinase (ITK). This dual mechanism of action is considered to have positive significance in the treatment of chronic graft-versus-host disease.

There is currently no clear data to support the safety and effectiveness of ibrutinib in children under 1 year old. In overseas markets, the common specifications of Bangladeshi generic drugs are 140mg*120 tablets, and the price is relatively affordable. The price per box is approximately between a few hundred to 1,000 yuan, but the specific price may change due to factors such as exchange rate fluctuations.